

Alessandro Gozzetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7549200/publications.pdf>

Version: 2024-02-01

231
papers

4,637
citations

117571

34
h-index

123376

61
g-index

236
all docs

236
docs citations

236
times ranked

5206
citing authors

#	ARTICLE	IF	CITATIONS
1	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.2	11
2	Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 984-990.	0.6	3
3	Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 9-10.	0.4	1
4	Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 171.	2.1	17
5	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563.	1.3	6
6	Drug resistance and minimal residual disease in multiple myeloma. <i>Cancer Drug Resistance (Alhambra)</i> , 2022, 10, 100000.	0.9	3
7	Daratumumab in AL Amyloidosis: A Real-Life Experience of the –RTM– (Regional Tuscan Myeloma) Study. <i>Frontiers in Oncology</i> , 2022, 12, 835563.	1.1	2
8	Editorial: Molecular Mechanisms of Multiple Myeloma. <i>Frontiers in Oncology</i> , 2022, 12, 870123.	1.3	1
9	A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05379.	0.2	1
10	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	2.0	12
11	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
12	Anti CD38 monoclonal antibodies for multiple myeloma treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	21
13	Assessing gene function in human B cells: CRISPR/Cas9-based gene editing and mRNA-based gene expression in healthy and tumor cells. <i>European Journal of Immunology</i> , 2022, 52, 1362-1365.	1.6	2
14	Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 92-96.	0.4	1
15	Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1897-1906.	0.6	1
16	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	3.3	28
17	The Role of Tumor-Associated Macrophages in Hematologic Malignancies. <i>Cancers</i> , 2021, 13, 3597.	1.7	31
18	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 900.	0.8	2
20	A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in E μ 1/4-TCL1 mice through the JNK/STAT4/p66Shc axis. <i>Pharmacological Research</i> , 2021, 174, 105965.	3.1	1
21	Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?. <i>Blood Research</i> , 2021, 56, 333-334.	0.5	2
22	First reported case of secondary mixed phenotype acute leukemia after multiple myeloma. <i>American Journal of Blood Research</i> , 2021, 11, 123-131.	0.6	4
23	OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S3.	0.2	2
24	Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes. <i>Blood</i> , 2021, 138, 2695-2695.	0.6	0
25	Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic. <i>Blood</i> , 2021, 138, 4680-4680.	0.6	0
26	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 115-115.	0.6	2
27	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	0.6	1
28	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Blood</i> , 2021, 138, 1479-1479.	0.6	1
29	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	2.8	126
30	Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T α cell lymphoblastic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2000-2002.	0.2	14
31	Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol. <i>Frontiers in Medicine</i> , 2020, 7, 466.	1.2	53
32	Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2020, 10, 120.	1.1	13
33	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19. <i>Leukemia</i> , 2020, 34, 2815-2816.	3.3	22
34	Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 570187.	1.3	11
35	Daratumumab efficacy in extramedullary orbital myeloma. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3652-3653.	0.2	3
36	CLL-251: Venetoclax for CLL Patients Outside Clinical Trials: An Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S225-S226.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146
38	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
39	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020, 105, 2671-2674.	1.7	1
40	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
41	Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial. <i>Blood</i> , 2020, 136, 44-45.	0.6	7
42	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	0.7	5
43	A BRAF-Negative Classic Hairy Cell Leukemia Patient with LongLasting Complete Remission after Rituximab and Pentostatin. <i>Turkish Journal of Haematology</i> , 2020, 37, 286-287.	0.2	3
44	Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region. <i>Farmeconomia E Percorsi Terapeutici</i> , 2020, 21, .	0.2	0
45	Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes with Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients with Chronic Lymphocytic Leukemia from Senegal. <i>Blood</i> , 2020, 136, 19-19.	0.6	0
46	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
47	Minimal Residual Disease (MRD) at 10-6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment) Tj ETQq1 DQ784314 rgBT /Ov	0.6	14
48	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
49	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
50	Hematogenous extramedullary relapse in multiple myeloma – a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	2.0	24
51	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	1.7	16
52	LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e147-e148.	0.2	1
53	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	0.7	28
54	DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response /MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e161-e162.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 657-659.	1.2	2
56	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 605-605.	0.6	3
57	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 8002-8002.	0.8	67
58	Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis. <i>Neurological Sciences</i> , 2018, 39, 593-594.	0.9	3
59	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	1.2	41
60	LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.	0.2	0
61	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.2	61
62	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	1.3	84
63	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	0.6	3
64	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	0.6	1
65	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 529-535.	2.0	20
66	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
67	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
68	Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2017, 130, 2006-2017.	0.6	12
69	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	0.8	7
70	Intravenous (<sc>IV</sc>) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to <sc>IV</sc> bortezomib?. <i>British Journal of Haematology</i> , 2017, 177, 144-147.	1.2	2
71	Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal. <i>American Journal of Clinical Pathology</i> , 2017, 148, 545-554.	0.4	6
72	Second Generation Proteasome Inhibitors in Multiple Myeloma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 920-926.	0.9	11

#	ARTICLE	IF	CITATIONS
73	Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 886-895.	0.9	7
74	Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1040-1045.	0.9	3
75	FLT3 Inhibitors in the Management of Acute Myeloid Leukemia. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1028-1032.	0.9	2
76	Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 124-127.	0.4	0
77	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
78	Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release. <i>Cell Reports</i> , 2016, 15, 9-18.	2.9	32
79	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
80	Central nervous system multiple myeloma. <i>Annals of Hematology</i> , 2016, 95, 519-520.	0.8	2
81	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
82	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	0.6	3
83	LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3211-3211.	0.6	2
84	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	0.8	26
85	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	0.6	0
86	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	0.6	0
87	Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2015, 56, 1916-1917.	0.6	1
88	Central Nervous System Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e133.	0.2	1
89	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <i>Leukemia Research</i> , 2015, 39, 1066-1070.	0.4	29
90	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. <i>Blood</i> , 2015, 126, 2946-2946.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Evolving Treatments in Multiple Myeloma Patients with Renal Failure. Reviews on Recent Clinical Trials, 2015, 9, 276-279.	0.4	0
92	Novel Agents in CNS Myeloma Treatment. Central Nervous System Agents in Medicinal Chemistry, 2014, 14, 23-27.	0.5	34
93	Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. Leukemia and Lymphoma, 2014, 55, 781-785.	0.6	8
94	Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. Cancer, 2014, 120, 451-452.	2.0	9
95	Central nervous system multiple myeloma: a different cytogenetic profile. British Journal of Haematology, 2014, 165, 889-890.	1.2	1
96	Therapeutic Advancements in Multiple Myeloma. Frontiers in Oncology, 2014, 4, 241.	1.3	53
97	Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. American Journal of Hematology, 2014, 89, 1085-1091.	2.0	45
98	Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leukemia Research, 2014, 38, 891-895.	0.4	12
99	Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. Haematologica, 2014, 99, e235-e237.	1.7	22
100	Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study. Blood, 2014, 124, 4734-4734.	0.6	2
101	Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience. Blood, 2014, 124, 5655-5655.	0.6	1
102	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. Annals of Hematology, 2013, 92, 1271-1280.	0.8	10
103	Treatment of smoldering multiple myeloma. Nature Reviews Clinical Oncology, 2013, 10, 724-724.	12.5	1
104	Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. Hematological Oncology, 2013, 31, 213-217.	0.8	10
105	Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer Journal, 2013, 3, e162-e162.	2.8	56
106	Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?. Blood, 2013, 122, 1482-1482.	0.6	6
107	Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM). Blood, 2013, 122, 1974-1974.	0.6	2
108	Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study. Blood, 2013, 122, 5309-5309.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Commentary. <i>Journal of Neurosciences in Rural Practice</i> , 2013, 4, 448.	0.3	0
110	Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. <i>Tumori</i> , 2013, 99, e193-202.	0.6	8
111	Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012041.	0.5	2
112	EBV Reactivation and Chromosomal Polysomies: <i>Euphorbia tirucalli</i> as a Possible Cofactor in Endemic Burkitt Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-11.	0.6	14
113	Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-4.	2.0	1
114	Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy. <i>Skeletal Radiology</i> , 2012, 41, 611-614.	1.2	12
115	Extramedullary myeloma relapses. <i>Annals of Hematology</i> , 2012, 91, 1511-1512.	0.8	8
116	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
117	Lenalidomide maintenance in myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 605-605.	12.5	3
118	Evaluation of residual CD34 ⁺ Ph ⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. <i>Cancer</i> , 2012, 118, 5265-5269.	2.0	13
119	Plasmacytoma of the skull. <i>European Journal of Haematology</i> , 2012, 88, 369-369.	1.1	9
120	Extramedullary multifocal plasmacytoma relapse in multiple myeloma. <i>Leukemia Research</i> , 2012, 36, e34-e36.	0.4	7
121	Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. <i>British Journal of Haematology</i> , 2012, 157, 497-498.	1.2	14
122	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients. <i>Cancer</i> , 2012, 118, 1574-1584.	2.0	102
123	A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report. <i>Leukemia Research</i> , 2011, 35, e206-e208.	0.4	7
124	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	1.5	67
125	Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 3530-3530.	2.0	0
126	Unusual localizations of plasmacytoma. <i>Leukemia Research</i> , 2011, 35, e104-e105.	0.4	1

#	ARTICLE	IF	CITATIONS
127	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. <i>Annals of Oncology</i> , 2011, 22, 1628-1635.	0.6	65
128	Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 317-317.	0.6	3
129	Molecular Cytogenetics Analysis of 13q14 Biallelic Deletion in Chronic Lymphocytic Leukemia: A Study on 250 Patients. <i>Blood</i> , 2011, 118, 1454-1454.	0.6	0
130	Hyperlipidemic myeloma. <i>Annals of Hematology</i> , 2010, 89, 939-940.	0.8	1
131	Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 84-85.	1.0	0
132	Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 76-80.	1.0	28
133	Thalidomide+dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. <i>European Journal of Haematology</i> , 2010, 84, 484-492.	1.1	31
134	Physicians and end-of-life issues. <i>Cancer</i> , 2010, 116, 3978-3978.	2.0	0
135	Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib. <i>Leukemia Research</i> , 2010, 34, e215-e216.	0.4	0
136	Hyperlipidemia in a myeloma patient after bortezomib treatment. <i>Leukemia Research</i> , 2010, 34, e250.	0.4	1
137	Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma. <i>Leukemia Research</i> , 2010, 34, e288-e289.	0.4	3
138	Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q deletion. <i>British Journal of Haematology</i> , 2010, 148, 483-484.	1.2	6
139	A der(1)t(1;21)(p36.3;q22) in a Patient with Acute Myelogenous Leukemia M2. <i>Acta Haematologica</i> , 2010, 124, 44-45.	0.7	0
140	Complete molecular response in CML after p210 BCR-ABL-derived peptide vaccination. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 600-603.	12.5	26
141	Lenalidomide efficacy in bortezomib-resistant myeloma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	12.5	1
142	Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 68-72.	0.2	16
143	Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 353-360.	0.2	4
144	Predicting the clinical course of Hodgkin lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	12.5	1

#	ARTICLE	IF	CITATIONS
145	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. Blood, 2010, 116, 3413-3413.	0.6	2
146	Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients. Blood, 2010, 116, 3562-3562.	0.6	6
147	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3578-3578.	0.6	0
148	Isolated deletion of 6q in a patient with myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 2009, 192, 51.	1.0	1
149	Cutaneous myeloma and bortezomib. Annals of Hematology, 2009, 88, 1045-1045.	0.8	2
150	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. British Journal of Haematology, 2009, 146, 64-75.	1.2	136
151	Bortezomib and restoration of chemosensitivity. Nature Reviews Clinical Oncology, 2009, 6, 1-1.	12.5	0
152	Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. Clinical Lymphoma and Myeloma, 2009, 9, 145-150.	1.4	36
153	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009, 114, 4939-4943.	0.6	62
154	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. Blood, 2009, 114, 648-648.	0.6	6
155	Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study.. Blood, 2009, 114, 1882-1882.	0.6	1
156	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.. Blood, 2009, 114, 4147-4147.	0.6	0
157	The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients. Calcified Tissue International, 2008, 82, 258-262.	1.5	23
158	Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology, 2008, 50, 665-674.	1.1	116
159	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematological Oncology, 2008, 26, 247-251.	0.8	36
160	CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia, 2008, 22, 426-428.	3.3	21
161	Reply to "Rituximab activity in CD20-positive multiple myeloma". Leukemia, 2008, 22, 1083-1083.	3.3	4
162	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. British Journal of Haematology, 2008, 142, 529-537.	1.2	78

#	ARTICLE	IF	CITATIONS
163	Concomitant chronic myeloid leukemia and chronic lymphocytic leukemia: a different clonal origin shown by molecular cytogenetics. <i>Cancer Genetics and Cytogenetics</i> , 2008, 180, 83-84.	1.0	4
164	Unusual Discordant Responses in Two Multiple Myeloma Patients during Bortezomib Treatment. <i>Onkologie</i> , 2008, 31, 45-47.	1.1	13
165	Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results. <i>Blood</i> , 2008, 112, 2768-2768.	0.6	2
166	Two Novel WT-1 Derived Peptides Induce CD4+ peptide-specific T Cell Proliferation in Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2008, 112, 5432-5432.	0.6	0
167	CMLVAX100 Peptide Vaccinations induce Peptide Specific α -cytotoxic-CD4+ T Cells (CD4+CTLs) in Chronic Myeloid Leukemia Patients: New Insights about Peptide Vaccine-Mediated Antitumor Response. <i>Blood</i> , 2008, 112, 3209-3209.	0.6	1
168	Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients. <i>Acta Haematologica</i> , 2007, 118, 7-9.	0.7	3
169	Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2434-2441.	0.8	329
170	Promyelocytic Blast Crisis of Chronic Myelogenous Leukemia during Imatinib Treatment. <i>Acta Haematologica</i> , 2007, 117, 236-237.	0.7	9
171	Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. <i>Haematologica</i> , 2007, 92, 564-565.	1.7	25
172	Insights into JAK2-V617F mutation in CML. <i>Lancet Oncology</i> , The, 2007, 8, 864-866.	5.1	50
173	Multiple Myeloma Involving the Cavernous Sinus: A Report of 3 Cases and Response to Bortezomib. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 376-378.	1.4	14
174	The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. <i>Hematological Oncology</i> , 2007, 25, 38-43.	0.8	37
175	Characterization of Ph-negative abnormal clones emerging during imatinib therapy. <i>Cancer</i> , 2007, 109, 2466-2472.	2.0	29
176	Reply to Rituximab activity in CD20 positive multiple myeloma. <i>Leukemia</i> , 2007, 21, 1842-1843.	3.3	7
177	Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007, 139, 90-93.	1.2	15
178	Trisomy 8 in chronic lymphocytic leukemia: a report of two cases. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 175-176.	1.0	3
179	Deletion 9q in a patient with concomitant myelodysplasia and non-Hodgkin lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 177.	1.0	3
180	Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 81-82.	1.0	5

#	ARTICLE	IF	CITATIONS
181	The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients.. Blood, 2007, 110, 4828-4828.	0.6	0
182	Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.. Blood, 2007, 110, 3997-3997.	0.6	1
183	Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.. Blood, 2007, 110, 4686-4686.	0.6	0
184	Activity of Rituximab Monotherapy in Refractory Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia. Clinical Lymphoma and Myeloma, 2006, 6, 496-499.	1.4	23
185	Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia, 2006, 20, 142-143.	3.3	16
186	Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission. Cancer Genetics and Cytogenetics, 2006, 167, 182.	1.0	0
187	Trisomy 22 as sole cytogenetic abnormality in acute monoblastic leukemia (M5b). Cancer Genetics and Cytogenetics, 2006, 169, 86.	1.0	1
188	Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: A metabolic adaptation?. Hematology, 2006, 11, 239-244.	0.7	7
189	Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.. Blood, 2006, 108, 800-800.	0.6	23
190	Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy.. Blood, 2006, 108, 2116-2116.	0.6	0
191	Zoledronic Acid Early Increases Serum Osteoprotegerin in Early Stage Multiple Myeloma.. Blood, 2006, 108, 3588-3588.	0.6	0
192	The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. Haematologica, 2006, 91, 1720-1.	1.7	12
193	Trisomy 13 in a patient with idiopathic myelofibrosis. Cancer Genetics and Cytogenetics, 2005, 156, 185.	1.0	0
194	Thrombotic Thrombocytopenic Purpura Secondary to an Occult Adenocarcinoma. Oncologist, 2005, 10, 299-300.	1.9	10
195	Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2005, 46, 793-793.	0.6	12
196	Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. Hematology, 2005, 10, 383-386.	0.7	13
197	Effect of a p210 multi-peptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet, The, 2005, 365, 657-662.	6.3	221
198	Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. Leukemia and Lymphoma, 2005, 46, 1837-1838.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Evaluation of Ph+/CD34+ Residual Cells in Chronic Myeloid Leukemia Patients after Long Lasting Treatment with Imatinib Mesylate.. Blood, 2005, 106, 1999-1999.	0.6	0
200	Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia. Hematology, 2004, 9, 405-407.	0.7	4
201	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. The Hematology Journal, 2004, 5, 472-474.	2.0	17
202	A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate. Cancer Genetics and Cytogenetics, 2004, 148, 152-154.	1.0	6
203	Effect of 5637 conditioned medium (CM) on the mitotic index in the cytogenetic evaluation of myeloproliferative disorders. Annales De G�n�tique, 2004, 47, 432-434.	0.4	0
204	A case of adult acute myelocytic leukemia (M5a) with a near-tetraploid karyotype characterized by monosomies 5 and 16. Cancer Genetics and Cytogenetics, 2004, 150, 88-89.	1.0	1
205	A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase. Cancer Genetics and Cytogenetics, 2004, 150, 90-91.	1.0	0
206	A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2004, 154, 193-194.	1.0	1
207	An unusual presentation of chronic B-cell lymphocytic leukaemia. British Journal of Haematology, 2004, 124, 129-129.	1.2	2
208	Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes and Cancer, 2004, 40, 179-189.	1.5	46
209	The Use of Fluorescence In Situ Hybridization (FISH) in Chronic Lymphocytic Leukemia (CLL). Hematology, 2004, 9, 11-15.	0.7	5
210	Molecular Cytogenetic Analysis of B-CLL Patients with Aggressive Disease. Hematology, 2004, 9, 383-385.	0.7	8
211	Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI). European Journal of Haematology, 2003, 71, 313-314.	1.1	14
212	A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement. Cancer Genetics and Cytogenetics, 2003, 144, 177-178.	1.0	7
213	Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues. Histopathology, 2003, 43, 491-494.	1.6	29
214	Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica, 2002, 87, 934-42.	1.7	30
215	Identification of novel cryptic translocations involving IGH in B-cell non-Hodgkin's lymphomas. Cancer Research, 2002, 62, 5523-7.	0.4	9
216	CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica, 2002, 87, 1135-40.	1.7	34

#	ARTICLE	IF	CITATIONS
217	Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization. <i>Leukemia</i> , 2001, 15, 1475-1484.	3.3	42
218	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2273-2281.	0.8	153
219	Fluorescence in situ hybridization: Uses and limitations. <i>Seminars in Hematology</i> , 2000, 37, 320-333.	1.8	120
220	Fluorescence in situ hybridization: Uses and limitations. <i>Seminars in Hematology</i> , 2000, 37, 320-333.	1.8	62
221	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 27-32.	1.3	54
222	Selection and Transplantation of Autologous Hematopoietic CD34+Cells for Patients with Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1997, 26, 1-11.	0.6	24
223	Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation for Lymphoma Patients. <i>Acta Haematologica</i> , 1996, 95, 164-170.	0.7	3
224	Monitoring Bulky Mediastinal Disease with Gallium-67, CT-Scan and Magnetic Resonance Imaging in Hodgkin's Disease and High-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 22, 131-135.	0.6	27
225	Adult Lymphoblastic Lymphoma: Clinical Features and Prognostic Factors in 53 Patients. <i>Leukemia and Lymphoma</i> , 1996, 23, 577-582.	0.6	55
226	Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation (ABMT) for Lymphoma Patients. , 1996, , 11-20.		0
227	6The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 795-813.	1.1	7
228	Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports. <i>Stem Cells</i> , 1995, 13, 126-131.	1.4	10
229	Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1993, 4, 575-578.	0.6	84
230	Fludarabine in patients with advanced and/or resistant Bâ€chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 1993, 51, 93-97.	1.1	28
231	Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6